InMed Pharmaceuticals filed a prospectus supplement to sell common shares under its amended At The Market sales agreement with H.C. Wainwright.
Key Highlights:
Filed prospectus supplement and related prospectus on April 3, 2026 under Form S-3 (File No. 333-294503).Share sales will occur pursuant to the At The Market Offering Agreement amended June 27, 2024 with H.C. Wainwright.Registration Statement was declared effective March 30, 2026, enabling sales under the shelf registration.Legal opinion on legality of common shares issuable under the Sales Agreement is filed as Exhibit 5.1.
Original SEC Filing: InMed Pharmaceuticals Inc. [ INM ] – 8-K – Apr. 03, 2026
Disclaimer
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.
